Safety and treatment patterns of multikinase inhibitors in @entity1 with XXXX at a tertiary oncology center in Italy.

@entity1 @entity3136 @entity2240 @entity294 @entity33 @entity2857 @entity1295 @entity1395 @entity1109 @entity1358 @entity8566
BACKGROUND: Multikinase inhibitors (MKIs) @entity2240 and @entity2857 have become a standard of care for @entity1358 ( @entity1358 ). This study assessed safety and treatment patterns for these agents in a real-world clinical practice setting in Italy. METHODS: A retrospective medical record review was performed at a tertiary oncology center in Italy. The study included MKI-na  ve non-trial @entity1 >= 18 years old, with a histological diagnosis of @entity1358 , and who received @entity2240 or @entity2857 as first MKI during 9/2005-7/2008. Data were collected on adverse events (AEs), treatment modifications (discontinuations, interruptions, dose changes), and reasons for these modifications. RESULTS: 145 @entity1 were included; 85 received @entity2240 and 60 received @entity2857 as first-line MKI. Median treatment duration was 6.6 ( @entity2240 ) and 5.8 ( @entity2857 ) months. 97.6% and 70.0% of @entity1 receiving @entity2240 and @entity2857 , respectively, experienced >= 1 AE; 27.1% and 31.7% had >= 1 grade 3/4 AE. The most common any grade AE for @entity2240 was @entity1295 / @entity1395 (81.2%), followed by @entity33 / @entity3136 (58.8%) and @entity1109 (42.4%), while for @entity2857 this was @entity1295 / @entity1395 (43.3%) followed by @entity8566 (38.3%) and @entity294 (31.7%). Treatment discontinuation, interruption, and dose reduction due to AEs occurred in 11.8%, 23.5%, and 30.6%, respectively, of @entity1 receiving @entity2240 , and 5.0%, 23.3%, and 36.7%, respectively, of @entity1 receiving @entity2857 . CONCLUSIONS: In this retrospective study, most @entity1 experienced >= 1 AE during first-line MKI treatment. AEs were reported frequently and resulted in treatment modifications in 40% of @entity1 receiving @entity2240 and 45% of @entity1 receiving @entity2857 . These results suggest a need for additional effective and more tolerable treatments for @entity1358 .
